Celgene Corp. buy tamam
Summary
This prediction ended on 21.07.16 with a price of €94.37. The price of Celgene Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.06%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Celgene Corp. | - | - | - | - |
iShares Core DAX® | -1.042% | 2.220% | 14.279% | 15.463% |
iShares Nasdaq 100 | -1.361% | 3.207% | 26.657% | 53.266% |
iShares Nikkei 225® | -0.044% | -1.680% | 5.941% | 4.271% |
iShares S&P 500 | -0.480% | 2.165% | 23.067% | 45.283% |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene: Time To Buy The Dip
The biotech sector has been hit hard in the recent sell-off in the overall markets. Major indices are down some 15% from recent highs; squarely in the correction territory.
The negative sentiment on this high beta sector of the market could last a while longer, but it is not too soon to start to accumulate the high quality names.
One of these is Celgene, which is down more than $20 a share from recent highs and offers a compelling combination of growth and value at these levels.